Which medications in the drug class PAH, Prostacyclin Agonists are used in the treatment of Pulmonary Arterial Hypertension?

Updated: Apr 25, 2018
  • Author: Kristin E Schwab, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print

PAH, Prostacyclin Agonists

Selexipag is the first prostacyclin agonist approved in the United States.

Selexipag (Uptravi)

Selexipag selectively activates the prostacyclin receptor (ie, IP-receptor), one of five types of prostanoid receptors. Unlike prostacyclin analogs, selexipag is selective for the IP receptor over other prostanoid receptors (ie, EP1-4, DP, FP, TP). Activating the IP receptor induces vasodilation and inhibits proliferation of vascular smooth muscle cells.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!